enlonstobart   Click here for help

GtoPdb Ligand ID: 13789

Synonyms: SG-001 | SG001
Approved drug
enlonstobart is an approved drug
Compound class: Antibody
Comment: Enlonstobart (SG001) is a fully humanised anti-PD-1 (PDCD1) monoclonal antibody. It was developed to treat advanced solid tumours by blocking the inhibitory the PD-1/PD-L1/L2 immune checkpoint.
No information available.
Summary of Clinical Use Click here for help
The Chinese drug regulator (NMPA) approved enlonstobart (Enshuxing®) in June 2024, to treat recurrent or metastatic programmed cell death ligand 1 (PD-L1)-positive cervical cancer that is insensitive to platinum-containing chemotherapy [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04886700 Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer Phase 2 Interventional CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 1
NCT03852823 Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours Phase 1 Interventional CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 3